Jose Diaz, MD
Pulmonary Disease · Leesburg, FLNPI 1659318608
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $118,625 of the $153,296 with a category attached, or 77.4%. GSK accounts for 79.0% of it on its own, with 56 other manufacturers making up the rest. Reporting peaked in 2022 at $34,307 and has fallen 70.5% since, to $10,106 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,026 payments — averaging $149.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$121K
- Pulmonx Corporation$6K
- Genentech USA, Inc.$5K
- AstraZeneca$3K
- Sanofi$2K
- Modernatx, Inc.$2K
- plus $14K from 51 others
Across 1,503 payments — averaging $7351.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$6.1M
- Astrazeneca UK Limited$1.3M
- GSK$1.1M
- Bavarian Nordic A/s$787K
- Boehringer Ingelheim$469K
- Merck$212K
- plus $1.1M from 20 others
What the payments were for
- Consulting fees$10,3357%
- Speaking & faculty fees$118,62577%
- Travel & lodging$2,6442%
- Food & beverage$21,09514%
- Education$5970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$82,232
- ZEPHYR ENDOBRONCHIAL VALVE$5,632
- ANORO ELLIPTA$3,600
- FASENRA$605
- AIRSUPRA$452
- BREZTRI$358
- DUPIXENT$245
- BRILINTA$231
- FLOWTRIEVER CATHETER, S$198
- CT THROMBECTOMY SYSTEM KIT$198
- CHARTIS CATHETER$153
- ZEPHYR DELIVERY CATHETER$153
- PULMONX CHARTIS TABLET CONSOLE$153
- OFEV$122
- UPTRAVI$121
- OPSUMIT$121
- NUCALA$119
- AREXVY$107
- ACTHAR$102
How this compares
$153,296 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 854 | $1,178,144 |
| OfevNintedanib Esylate | 23 | $298,188 |
| Dupixent PenDupilumab | 65 | $297,403 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 147 | $175,205 |
| OpsumitMacitentan | 14 | $165,995 |
| Spiriva RespimatTiotropium Bromide | 109 | $140,130 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $135,800 |
| NucalaMepolizumab | 24 | $100,770 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 73 | $86,242 |
| Breo ElliptaFluticasone/Vilanterol | 82 | $71,201 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 59 | $63,228 |
| SymbicortBudesonide/Formoterol Fumarate | 71 | $30,415 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 154 | $27,293 |
| Arnuity ElliptaFluticasone Furoate | 44 | $25,462 |
| Incruse ElliptaUmeclidinium Bromide | 50 | $23,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $121,032 | $1,485,0721,127 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,732 | $523,332206 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,621 | $205,620218 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,359 | $165,99514 claims |
| Grifols USA, LLCProlastin C | $842 | $135,80013 claims |
| PfizerEliquis | $17 | $11,71714 claims |
| MerckDulera | $80 | $7,82412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Leesburg
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.